frexalimab (SAR441344) - Sanofi
https://www.abstractsonline.com/pp8/#!/21408/presentation/504
 
B. Djukic1; R. Gandhi1; G. Boldina2; V. Truong3; N. Ternes4; B. Zhang1; M. Levit1; P. Krishnaswami1; S. S. Geertsen1; S. Saubadu5; P. Truffinet5; H. Wiendl6,7; T. Chitnis8; A. Bar-Or9; on behalf of the Frexalimab Phase 2 Trial Group
 
Feb 4, 2026
 
Next